Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 4/20 | 0.33 |
| ▸ | TNKS | O95271 | 2/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645290 | 0.84 | AKR1B1 (0.40) | ALDH1A1MAPTAKR1B1SLC6A5 | |
| SCHEMBL23685984 | 0.79 | ALDH1A1 (0.38) | KDM1AALDH1A1MAPTPARP1PARP10 | |
| SCHEMBL23645294 | 0.77 | ALDH1A1 (0.39) | ALDH1A1MAPTAKR1B1SLC6A5 | |
| SCHEMBL30291257 | 0.75 | KDM1A (0.49) | KDM1AMAPTPARP1AKR1B1PARP10 | |
| SCHEMBL23645191 | 0.75 | KDM1A (0.49) | KDM1AMAPTPARP1AKR1B1PARP10 | |
| SCHEMBL23630258 | 0.70 | KDM1A (0.40) | KDM1AALDH1A1MAPTTNKSTNKS2 | |
| SCHEMBL23645119 | 0.67 | KDM1A (0.39) | KDM1A | |
| SCHEMBL23644311 | 0.67 | SLC6A5 (0.34) | ALDH1A1MAPTTNKSTNKS2SLC6A5 | |
| SCHEMBL30291229 | 0.67 | SLC6A5 (0.34) | ALDH1A1MAPTTNKSTNKS2SLC6A5 | |
| SCHEMBL30676955 | 0.65 | ALDH1A1 (0.50) | ALDH1A1MAPTSLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021139748-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | KRAS, NRAS, HRAS | KDM1A 3827/4885ALDH1A1 349/4885MAPT 4687/4885 |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | KRAS, NRAS, HRAS | KDM1A 3827/4885ALDH1A1 349/4885MAPT 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.